Luciole Pharmaceuticals

Undisclosed ED obesity, metabolic syndrome

Luciole Pharmaceuticals is developing small molecules that can accelerate repair of mitochondria. Mitochondria are the energy producers of the cell and consequently many age-related diseases are linked with mitochondrial dysfunction, oxidative stress and inflammation. Much of this dysfunction can be linked back to damage to mitochondrial DNA. Luciole is identifying molecules that can activate the protein OGG1, which is a protein that can recognise and repair DNA damage in the mitochondria. These small molecules would have the potential to treat patients with neurodegenerative disease or obesity and metabolic syndromes.

Jobs: